{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:16:34Z","timestamp":1789992994461,"version":"4.0.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pulmonary embolism (PE) at initial diagnosis and during first-line systemic treatment is clinically relevant in patients with lung cancer. However, real-world incidence of subclinical PE is not well established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective single-center analysis of patients at least 18 years old with non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) who received first-line\/induction systemic therapy. All patients underwent contrast-enhanced computed tomography (CT) of the thorax with bolus tracking for PE detection. Treatment response was assessed by restaging at weeks 6 and 12 after treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 373 patients treated between 2019 and 2022 were included (261 NSCLC, 112 SCLC; 179 women and 194 men; median age 66 years [range, 22\u00a0to 86]; median smoking history 40 Pack Years [range, 0-150]). There was a predominance of locally advanced and metastatic disease (IB-IIB, n = 22; IIIA-C, n\u00a0= 123; IVA-B, n = 228). Adenocarcinoma was the predominant histology among NSCLC cases (LUAD, n = 146), followed by squamous cell carcinoma and other NSCLC subtypes combined (n = 115); 112 patients had SCLC.<\/jats:p>\n                    <jats:p>PE was detected in 61\/373 patients, of whom 58 (95%) had subclinical PE. In NSCLC, body-mass-index (BMI) was independently associated with occurrence of PE (OR = 1.111, p\u00a0=\u00a00.005), while central tumor localization (OR 5.637, p\u00a0=\u00a00.028) and vascular infiltration (OR 7.683, p = 0.010) were significantly associated with PE in SCLC. All patients with PE received anticoagulants according to national and international guidelines and no PE-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This single-center analysis demonstrates a high incidence of subclinical PE in newly diagnosed lung cancer patients and identifies clinical risk factors associated with PE development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1886848","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:59:19Z","timestamp":1789991959000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Subclinical pulmonary embolism in first-line\/induction therapy of lung cancer -\u00a0a remaining clinically relevant adverse event"],"prefix":"10.3389","volume":"16","author":[{"given":"Kristin","family":"Mersmann","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen","place":["Essen, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Metzenmacher","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen","place":["Essen, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]},{"name":"Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Zaun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen","place":["Essen, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Wiesweg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen","place":["Essen, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filiz","family":"Oezkan","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Winantea","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Taube","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Theegarten","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]},{"name":"Department of Pathology, West German Cancer Center, University Hospital Essen","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen","place":["Essen, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]},{"name":"Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]},{"name":"Institute of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Servet","family":"B\u00f6l\u00fckbas","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]},{"name":"Department of Thoracic Surgery, University Medicine Essen \u2013 Ruhrlandklinik","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Doerr","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]},{"name":"Department of Thoracic Surgery, University Medicine Essen \u2013 Ruhrlandklinik","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Messiha","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Centre, University of Duisburg-Essen","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Opitz","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]},{"name":"Institute of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried EE","family":"Eberhardt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Center, University Hospital Essen","place":["Essen, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["NCT West, Essen, Germany"]},{"name":"Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Wienker","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik","place":["Essen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.3.9806130","article-title":"Accuracy of clinical assessment in the diagnosis of pulmonary embolism","volume":"159","author":"Miniati","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(71)90116-0","article-title":"The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease","volume":"28","author":"McIntyre","year":"1971","journal-title":"Am J Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/crj.13270","article-title":"Analysis on risk factors of lung cancer complicated with pulmonary embolism","volume":"15","author":"Cui","year":"2021","journal-title":"Clin Respir J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231158368","article-title":"Prevalence of cancer in patients with venous thromboembolism: A retrospective nationwide case-control study in Sweden","volume":"29","author":"Glise Sandblad","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25941","article-title":"Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center","volume":"117","author":"Shinagare","year":"2011","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656542","article-title":"Clinical characteristics and outcomes of patients with lung cancer and venous thromboembolism","volume":"2","author":"Ruiz-Artacho","year":"2018","journal-title":"TH Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.05.071","article-title":"Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry)","volume":"57","author":"Pollack","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2013.06.003","article-title":"Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients","volume":"14","author":"Connolly","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae Insights: Non-small cell lung cancer, Version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4266","article-title":"Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus","volume":"25","author":"Carrier","year":"2018","journal-title":"Curr Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02082.x","article-title":"Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry","volume":"4","author":"Monreal","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patients with Malignancy versus those without Malignancy. Risk analysis using Medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Med (Baltimore)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2022.63","article-title":"The 2022 european society of cardiology cardio-oncology guidelines in focus","volume":"18","author":"Gent","year":"2023","journal-title":"Eur Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.thromres.2016.01.002","article-title":"Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study","volume":"139","author":"Ashrani","year":"2016","journal-title":"Thromb Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2390200","article-title":"Incidence and risk factors of VTE in lung cancer: a meta-analysis","volume":"56","author":"Yang","year":"2024","journal-title":"Ann Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/10760296241311902","article-title":"Clinical characteristics and risk factors of patients with lung cancer complicated with pulmonary embolism: A case control study","volume":"31","author":"Wang","year":"2025","journal-title":"Clin Appl Thromb Hemost"},{"key":"B20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.cllc.2024.04.004","article-title":"Risk of venous thromboembolism in patients with stage III and IV non-small-cell lung cancer: Nationwide descriptive cohort study","volume":"25","author":"Ording","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3892\/ol.2022.13288","article-title":"Characteristics and outcomes of cancer patients who develop pulmonary embolism: A cross-sectional study","volume":"23","author":"Chlapoutakis","year":"2022","journal-title":"Oncol Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006072","article-title":"Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer","volume":"11","author":"Khorana","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B26","article-title":"S3-Leitlinie Prophylaxe der ven\u00f6sen Thromboembolie (VTE), Langversion 4.1","author":"Arbeitsgemeinschaft","year":"2025"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e977","DOI":"10.1161\/CIR.0000000000001415","article-title":"2026 AHA\/ACC\/ACCP\/ACEP\/CHEST\/SCAI\/SHM\/SIR\/SVM\/SVN guideline for the evaluation and management of acute pulmonary embolism in adults: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Creager","year":"2026","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12672-025-02720-y","article-title":"Incidence of pulmonary embolism and its risk factors in lung cancer patients: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2025","journal-title":"Discov Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02987.x","article-title":"Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation","volume":"6","author":"Davila","year":"2008","journal-title":"J Thromb Haemost"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02369.x","article-title":"Microparticle-associated tissue factor activity: a link between cancer and thrombosis","volume":"5","author":"Tesselaar","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14911","article-title":"Risk factors for venous thromboembolism in patients with small cell lung cancer","volume":"41","author":"Dimakakos","year":"2021","journal-title":"Anticancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-160580","article-title":"Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis","volume":"16","author":"Zhang","year":"2016","journal-title":"Cancer biomark"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.10.003","article-title":"Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours","volume":"69","author":"Gizzi","year":"2016","journal-title":"Eur J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.03.012","article-title":"Obesity as a risk factor in venous thromboembolism","volume":"118","author":"Stein","year":"2005","journal-title":"Am J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvx086","article-title":"New insights into the role of adipose tissue in thrombosis","volume":"113","author":"Vilahur","year":"2017","journal-title":"Cardiovasc Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2019.06.013","article-title":"Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients","volume":"75","author":"Hiraide","year":"2020","journal-title":"J Cardiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12714","article-title":"Pulmonary embolism and deep vein thrombosis-comorbidities and temporary provoking factors in a register-based study of 1.48 million people","volume":"6","author":"Glise Sandblad","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110190","article-title":"Diabetes mellitus is associated with a higher relative risk for venous thromboembolism in females than in males","volume":"194","author":"Deischinger","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01935","article-title":"Thromboembolic events during perioperative therapy for resectable and borderline resectable pancreatic cancer in the PREOPANC-2 trial","volume":"44","author":"Willems","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1886848\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:59:20Z","timestamp":1789991960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1886848\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":40,"alternative-id":["10.3389\/fonc.2026.1886848"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1886848","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1886848"}}